What is the evaluation and treatment approach for a patient with hyperandrogenism, specifically with elevated DHEA and testosterone levels, suspected of having Polycystic Ovary Syndrome (PCOS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Evaluation of Elevated DHEA-S and Testosterone in Suspected PCOS

Your patient's elevated DHEA-S (314) and testosterone (60) support biochemical hyperandrogenism, but you should prioritize measuring total testosterone and calculated free testosterone (or FAI) using LC-MS/MS as first-line tests, as DHEA-S has poor diagnostic specificity for PCOS and should only be considered when testosterone-based measurements are equivocal. 1, 2

Diagnostic Approach to Androgen Measurement

First-Line Testing Strategy

  • Measure total testosterone (TT) and free testosterone (FT) as your primary diagnostic tests for biochemical hyperandrogenism in PCOS, as these have the highest sensitivity (0.74 for TT, 0.89 for cFT) and specificity (0.86 for TT, 0.83 for cFT) with AUCs of 0.87 and 0.85 respectively 1

  • Calculate free testosterone using the Free Androgen Index (FAI) when direct measurement is unavailable, as FAI demonstrates sensitivity of 0.78 and specificity of 0.85 with an AUC of 0.87 1

  • Ensure SHBG levels are ≤170 nmol/L before relying on calculated free testosterone, as values above this threshold produce unreliable calculations due to excessive SHBG fluctuations 3

Role of DHEA-S in Diagnosis

  • DHEA-S has limited diagnostic utility with pooled sensitivity of only 0.75 and specificity of 0.67 (AUC 0.77), making it significantly inferior to testosterone-based measurements 1, 2

  • Consider DHEA-S only as a second-line marker when first-line testosterone tests are negative but clinical suspicion remains high, or when signs of virilization are present 2, 4

  • Age-adjusted reference ranges are essential for DHEA-S interpretation, as levels decline approximately 2% per year after age 20-30, and failure to use age-specific norms leads to overdiagnosis 2, 5

  • In women aged 20-29 years, elevated DHEA-S occurs in only 8-11% of PCOS cases (33% in non-age-adjusted studies), and is more common in non-classic phenotypes B and C than phenotype A 5, 6

Assay Method Considerations

LC-MS/MS vs Immunoassay

  • LC-MS/MS is the preferred method for androgen measurement due to superior accuracy, with higher sensitivity for calculated free testosterone (0.89 vs 0.74), FAI (0.89 vs 0.74), and androstenedione (0.86 vs 0.64) compared to direct immunoassays 1

  • For DHEA-S specifically, LC-MS/MS shows higher sensitivity (0.82) but lower specificity (0.57) compared to direct immunoassays (sensitivity 0.67, specificity 0.70), though differences are less pronounced than for testosterone 1, 2

Excluding Other Causes of Hyperandrogenism

When to Suspect Androgen-Secreting Tumors

  • Measure testosterone and DHEA-S to screen for neoplasms when severe virilization with recent onset is present, though the positive predictive value is only 9% for testosterone >8.7 nmol/L (250 ng/dL) 4, 7

  • Total testosterone >8.7 nmol/L has 100% sensitivity and 98% specificity for androgen-secreting tumors, but occurs in only 2.3% of hyperandrogenic patients 7

  • DHEA-S >16.3 μmol/L (6000 ng/mL) should prompt adrenal imaging, though the positive predictive value for adrenal tumors is extremely low in the absence of rapid virilization 7

Other Differential Diagnoses

  • Exclude non-classical congenital adrenal hyperplasia (NCCAH) by measuring basal or ACTH-stimulated 17-hydroxyprogesterone, particularly if oligomenorrhea began after menarche 4

  • Rule out Cushing's disease with overnight dexamethasone suppression test or 24-hour urinary free cortisol if signs of hypercortisolism accompany recent-onset hyperandrogenism 4

  • Check prolactin levels in women with recent-onset oligomenorrhea and mild hyperandrogenism to exclude hyperprolactinemia 4

Completing the PCOS Diagnosis

Rotterdam Criteria Application

  • Diagnose PCOS when two of three criteria are met: ovulatory dysfunction, clinical or biochemical hyperandrogenism, and polycystic ovary morphology on ultrasound or elevated anti-Müllerian hormone 1

  • Rotterdam criteria show higher sensitivity (0.77) but lower specificity (0.83) compared to NIH criteria (sensitivity 0.51, specificity 0.94) for biochemical hyperandrogenism diagnosis 1

Common Pitfalls to Avoid

  • Do not use DHEA-S as a first-line test for PCOS diagnosis due to poor specificity and low prevalence of elevation, as only 8.1% of PCOS patients have truly elevated age-adjusted DHEA-S 2, 5

  • Avoid relying on calculated free testosterone when SHBG >170 nmol/L, as this produces inaccurate results; use equilibrium dialysis for direct measurement instead 3

  • Do not screen for androgen-secreting tumors based solely on androgen levels without clinical features of rapid virilization, as the low frequency and poor positive predictive value make this cost-ineffective 7

  • Ensure blood samples are collected in the morning (8-10 AM) when testosterone levels are highest for accurate assessment 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

DHEA-S Testing in Clinical Practice

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

SHBG Values and Free Testosterone Calculation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Differential diagnosis of hyperandrogenism in women with polycystic ovary syndrome.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2012

Research

Is it useful to measure DHEAS levels in PCOS?

Annales d'endocrinologie, 2024

Research

Total testosterone and DHEAS levels as predictors of androgen-secreting neoplasms: a populational study.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 1999

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.